Transforming Drug Discovery :
factory-level platform,
forging breakthroughs in speed and accuracy
factory-level platform,
forging breakthroughs in speed and accuracy
Pioneering drug discovery with supercomputing integration and advanced AI, delivering a Factory-level automated platform (AI Bio-Supercom Center). Efficiently generates LaunchPad for 100+ diseases targets without interruption. LaunchPad, which is readily available ("off-the-shelf"), is being utilized to generate and validate drug candidates with the potential to obtain Investigational New Drug (IND) status.
Show More
Unlocking Efficiency :
CLOUD SaaS Technology
CLOUD SaaS Technology
Software as a Service (SaaS) allows researchers to concentrate on their work without the need for complex IT infrastructure, thereby expediting research progress and streamlining processes. Continual refinement of SaaS programs is essential to tackle evolving challenges and technological limitations, providing researchers with gradual enhancements that aid in their pursuit of innovative discoveries, one step at a time
Show More
Accelerating drug discovery :
finding shortest way
finding shortest way
Small Molecule DRUG candidate : DEEPMATCHER
DeepMatcher® utilizes AI to predict the three-dimensional structure of protein-compound
binding, calculate binding affinities, and select optimal structures. Through molecular
dynamics simulations, thereby yielding more accurate results.
Neoantigen prediction platform: NEO scan
NEO scan is an AI platform for predicting neoantigens, capable of 1) developing personalized
cancer vaccines and 2) applying to the development of universal (off-the-shelf) cancer
vaccines.
Antibody DRUG candidate : Ab scan
Ab scan is an Insilico antibody CDR prediction platform.
Our Service
Innovation in independent
LaunchPad
One-stop-shop with technologies and services to rapidly generate and optimize drug candidates from target to IND-enabling
Pre-made Based Factory-Like Platform
Our disease-agnostic platform continuously generates a constant stream of hits, leads, and
drug candidates that are readily available for purchase.
We also provide tailored drug discovery services.
Not Only Discovery, Add Your Choice!
SaaS
Cloud-based AI automates drug development and genomics analysis, tailoring discoveries to customer needs.
Software as a Service
Our company has functionally segmented the entire process of AI drug development and clinical genomics analysis into step-by-step modules and created the "CLOUD-SaaS” service applying cloud supercomputing automation processes. Each service is readily accessible on our STB Cloud website.
Discovery & Development
Unmatched supercomputing to support your drug discovery & development projects
Discovery & Development
This is the one-stop service based on the ‘DEEPMATCHER’ technology. This comprehensive service, from AI-based hit screening to preclinical candidate materials within two years, offers an end-to-end package solution, adept at addressing your challenging issues and demands to mitigate drug development risks.
Pre-made Based Factory-Like Platform
Our disease-agnostic platform continuously generates a constant stream of hits,
leads, and
drug candidates that are readily available for purchase. We also provide tailored drug discovery
services. Not Only Discovery, Add Your Choice!
Software as a Service
Our company has functionally segmented the entire process of AI drug development and clinical genomics analysis into step-by-step modules and created the "CLOUD-SaaS” service applying cloud supercomputing automation processes. Each service is readily accessible on our STB Cloud website.
Discovery & Development
This is the one-stop service DDC (Deepmatcher Drug Candidate) based on the 'Deepmatcher' technology. This service, starting from AI-based hit screening for targets to in-vitro validation, completes the derivation of preclinical candidate substances within two years, offering a comprehensive A to Z package service.
On Air
We lead with AI and supercomputing technology
Our archive
The Way of the Syntekabio
Our Archive
ABS
Supercom Center
Our established ABS center adopts state-of-the-art supercomputing technology to continuously explore new drug candidates. Through this, we provide high-quality services and products to our customers.
STB CLOUD SaaS
With excellent automation and distributed processing technology in the STB cloud, we can screen a library of one billion compounds.
Druggable compound
LaunchPad
The protein targets of the pre-made candidates cover 60-70% of major diseases currently under development. Syntekabio has identified over 100 targets to accelerate the discovery of new drug candidates and provide medications to more patients.
AI-automation
DEEPMATCHER
Small Molecule Drug, Neo-Antigen-Vaccine, Cell therapy, Antibody Drug, Drug Repurposing, Combination Therapy, Biomarker, Clinical Genomic Analysis
our partners
We work together for your personal
We work together for your personal
health and happiness
OUR LATEST NEWS
-
QIMR Berghofer engages AI partner to fast-track cancer drug discovery
2023-12-14
-
.jpg)
Syntekabio Partners with PDC Line Pharma to Develop Targeted Cancer Vaccine
2023-09-26
-
Syntekabio and Metaclipse sign MOU for Joint Research on Personalized Immunotherapy for Cancer
2023-07-31
-
.png)
A.I. in New Drug Discovery and Development Takes Center Stage at New York Health Forum
2022-12-14
